PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

Ruggero De Maria Marchiano, Giovanni Sette, Michele Milella, Italia Falcone, Fabiana Conciatori, Silvia Matteoni, Andrea Sacconi, Teresa De Luca, Chiara Bazzichetto, Vincenzo Corbo, Michele Simbolo, Isabella Sperduti, Antonina Benfante, Anais Del Curatolo, Ursula Cesta Incani, Federico Malusa, Adriana Eramo, Aldo Scarpa, Marina Konopleva, Michael AndreeffJames Andrew Mccubrey, Giovanni Blandino, Matilde Todaro, Giorgio Stassi, Francesco Cognetti, Donatella Del Bufalo, Ludovica Ciuffreda

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

36 Citazioni (Scopus)

Abstract

Combined MAPK/PI3K pathway inhibition represents an attractive, albeit toxic, therapeutic strategy in oncology. Since PTEN lies at the intersection of these two pathways, we investigated whether PTEN status determines the functional response to combined pathway inhibition. PTEN (gene, mRNA, and protein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR inhibition displayed highly synergistic pharmacologic interactions almost exclusively in PTEN-loss models. Genetic manipulation of PTEN status con rmed a mechanistic role for PTEN in determining the functional outcome of combined pathway blockade. Proteomic analysis showed greater phosphoproteomic pro le modi cation(s) in response to combined MEK/mTOR inhibition in PTEN- loss contexts and identi ed JAK1/STAT3 activation as a potential mediator of synergistic interactions. Overall, our results show that PTEN-loss is a crucial determinant of synergistic interactions between MAPK and PI3K pathway inhibitors, potentially exploitable for the selection of cancer patients at the highest chance of bene t from combined therapeutic strategies.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
Numero di pagine15
RivistaScientific Reports
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • PTEN
  • mTOR

Fingerprint

Entra nei temi di ricerca di 'PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer'. Insieme formano una fingerprint unica.

Cita questo